These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 11810736)
41. Deep Venous Thrombosis and Pulmonary Embolism: Current Therapy. Wilbur J; Shian B Am Fam Physician; 2017 Mar; 95(5):295-302. PubMed ID: 28290648 [TBL] [Abstract][Full Text] [Related]
42. [Conventional or low molecular weight heparin in the treatment of venous thromboembolic disease?]. Ruiz Manzano J; Monreal M Med Clin (Barc); 1998 Nov; 111(18):697-9. PubMed ID: 9887434 [No Abstract] [Full Text] [Related]
43. Low-molecular-weight heparins are essentially the same for treatment and prevention of venous thromboembolism. Lopez LM Pharmacotherapy; 2001 Jun; 21(6 Pt 2):56S-61S; discussion 71S-72S. PubMed ID: 11401194 [TBL] [Abstract][Full Text] [Related]
44. Is once- or twice-a-day enoxaparin as effective as unfractionated heparin for the treatment of venous thromboembolism (VTE)? Marsland T; Newton W J Fam Pract; 2001 May; 50(5):396. PubMed ID: 11350700 [No Abstract] [Full Text] [Related]
45. Enoxaparin for the prevention of VT in acutely ill patients. Tseng CW; Huntington J J Fam Pract; 1999 Dec; 48(12):940-1. PubMed ID: 10628571 [No Abstract] [Full Text] [Related]
46. Retrospective database analysis of the prevention of venous thromboembolism with low-molecular-weight heparin in acutely III medical inpatients in community practice. McGarry LJ; Thompson D Clin Ther; 2004 Mar; 26(3):419-30. PubMed ID: 15110135 [TBL] [Abstract][Full Text] [Related]
47. Cost comparison of at-home treatment of deep venous thrombosis with low molecular weight heparin to inpatient treatment with unfractionated heparin. Smith BJ; Weekley JS; Pilotto L; Howe T; Beven R Intern Med J; 2002; 32(1-2):29-34. PubMed ID: 11783670 [TBL] [Abstract][Full Text] [Related]
50. Enoxaparin for the prevention of venous thromboembolism. Calderon EJ; Varela JM; Gonzalez de la Puente MA N Engl J Med; 2000 Jan; 342(2):136-7. PubMed ID: 10636758 [No Abstract] [Full Text] [Related]
52. The economic implications of switching to rivaroxaban from enoxaparin plus vitamin K antagonist in the treatment of venous thromboembolism. Patel AA; Ogden K; Mody SH; Bookhart B J Med Econ; 2015 May; 18(5):323-32. PubMed ID: 25557176 [TBL] [Abstract][Full Text] [Related]
53. Venous thrombosis after acute spinal cord injury: cost analysis of prophylaxis guidelines. Wade WE; Chisholm MA Am J Phys Med Rehabil; 2000; 79(6):504-8. PubMed ID: 11083299 [TBL] [Abstract][Full Text] [Related]
54. [Clexane in prevention of acute venous thrombosis and pulmonary thromboembolism]. Kirienko AI; Zolotukhin IA Ter Arkh; 1998; 70(11):78-80. PubMed ID: 9949471 [No Abstract] [Full Text] [Related]